Myeloid cell leukemia-1 is a key molecular target for mithramycin A-induced apoptosis in androgen-independent prostate cancer cells and a tumor xenograft animal model

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 65-72

  Choi, Eun Sun ^a   Jung, Ji Youn ^b   Lee, Jin Seok ^b   Park, Jong Hwan ^c   Cho, Nam Pyo ^a   Cho, Sung Dae ^a  

^a Chonbuk National University   (South Korea)

^b Kongju National University   (South Korea)

^c Konyang University   (South Korea)

Author keywords

Apoptosis; Mcl 1; Mithramycin A; Prostate cancer; Xenograft

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; MESSENGER RNA; MITHRAMYCIN A; PROTEASOME; PROTEIN MCL 1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL GROWTH; CELL TRANSFORMATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; TUMOR XENOGRAFT;

ANDROGENS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DOWN-REGULATION; FEMALE; MALE; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; PLICAMYCIN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; MUS MUSCULUS;

EID: 84868468036     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.09.009     Document Type: Article

References (35)

1. Damber J.E., Aus G. Prostate cancer. Lancet 2008, 371:1710-1721.
2. Annual Report of the Korea Central Cancer Registry 2010, National Cancer Center, Ministry of Health and Welfare, Republic of Korea, 2010.
3. Rove K.O., Crawford E.D. Dutasteride: novel milestones in prostate cancer chemoprevention. Drugs Today (Barc) 2011, 47:135-144.
4. Lombo F., Menendez N., Salas J.A., Mendez C. The aureolic acid family of antitumor compounds: structure, mode of action, biosynthesis, and novel derivatives. Appl. Microbiol. Biotechnol. 2006, 73:1-14.
5. Koller C.A., Miller D.M. Preliminary observations on the therapy of the myeloid blast phase of chronic granulocytic leukemia with plicamycin and hydroxyurea. New Engl. J. Med. 1986, 315:1433-1438.
6. Seznec J., Silkenstedt B., Naumann U. Therapeutic effects of the Sp1 inhibitor mithramycin A in glioblastoma. J. Neurooncol. 2011, 101:365-377.
7. Lin R.K., Hsu C.H., Wang Y.C. Mithramycin A inhibits DNA methyltransferase and metastasis potential of lung cancer cells. Anticancer Drugs 2007, 18:1157-1164.
8. Malek A., Nunez L.E., Magistri M., Brambilla L., Jovic S., Carbone G.M., Moris F., Catapano C.V. Modulation of the activity of sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer. PLoS One 2012, 7:e35130.
9. Craig R.W. MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia 2002, 16:444-454.
10. Gojo I., Zhang B., Fenton R.G. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res. 2002, 8:3527-3538.
11. Kaufmann S.H., Karp J.E., Letendre L., Kottke T.J., Safgren S., Greer J., Gojo I., Atherton P., Svingen P.A., Loegering D.A., Litzow M.R., Sloan J.A., Reid J.M., Ames M.M., Adjei A.A., Erlichman C. Phase I and pharmacologic study of infusional topotecan and carboplatin in relapsed and refractory acute leukemia. Clin. Cancer Res. 2005, 11:6641-6649.
12. Zhou P., Qian L., Kozopas K.M., Craig R.W. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 1997, 89:630-643.
13. Arbour N., Vanderluit J.L., Le Grand J.N., Jahani-Asl A., Ruzhynsky V.A., Cheung E.C., Kelly M.A., MacKenzie A.E., Park D.S., Opferman J.T., Slack R.S. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J. Neurosci. 2008, 28:6068-6078.
14. Opferman J.T., Iwasaki H., Ong C.C., Suh H., Mizuno S., Akashi K., Korsmeyer S.J. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science 2005, 307:1101-1104.
15. Weber A., Boger R., Vick B., Urbanik T., Haybaeck J., Zoller S., Teufel A., Krammer P.H., Opferman J.T., Galle P.R., Schuchmann M., Heikenwalder M., Schulze-Bergkamen H. Hepatocyte-specific deletion of the antiapoptotic protein myeloid cell leukemia-1 triggers proliferation and hepatocarcinogenesis in mice. Hepatology 2010, 51:1226-1236.
16. Nagata M., Wada K., Nakajima A., Nakajima N., Kusayama M., Masuda T., Iida S., Okura M., Kogo M., Kamisaki Y. Role of myeloid cell leukemia-1 in cell growth of squamous cell carcinoma. J. Pharmacol. Sci. 2009, 110:344-353.
17. Schulze-Bergkamen H., Fleischer B., Schuchmann M., Weber A., Weinmann A., Krammer P.H., Galle P.R. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer 2006, 6:232.
18. Song L., Coppola D., Livingston S., Cress D., Haura E.B. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol. Ther. 2005, 4:267-276.
19. Gao Y., Jia Z., Kong X., Li Q., Chang D.Z., Wei D., Le X., Suyun H., Huang S., Wang L., Xie K. Combining betulinic acid and mithramycin a effectively suppresses pancreatic cancer by inhibiting proliferation, invasion, and angiogenesis. Cancer Res. 2011, 71:5182-5193.
20. Jia Z., Gao Y., Wang L., Li Q., Zhang J., Le X., Wei D., Yao J.C., Chang D.Z., Huang S., Xie K. Combined treatment of pancreatic cancer with mithramycin A and tolfenamic acid promotes Sp1 degradation and synergistic antitumor activity. Cancer Res. 2010, 70:1111-1119.
21. Yuan P., Wang L., Wei D., Zhang J., Jia Z., Li Q., Le X., Wang H., Yao J., Xie K. Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer. Cancer 2007, 110:2682-2690.
22. Choi E.S., Shim J.H., Jung J.Y., Kim H.J., Choi K.H., Shin J.A., Nam J.S., Cho N.P., Cho S.D. Apoptotic effect of tolfenamic acid in androgen receptor-independent prostate cancer cell and xenograft tumor through specificity protein 1. Cancer Sci. 2011, 102:742-748.
23. Nijhawan D., Fang M., Traer E., Zhong Q., Gao W., Du F., Wang X. Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev. 2003, 17:1475-1486.
24. Dai Y., Rahmani M., Grant S. Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 2003, 22:7108-7122.
25. Derouet M., Thomas L., Cross A., Moots R.J., Edwards S.W. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J. Biol. Chem. 2004, 279:26915-26921.
26. Iglesias-Serret D., Pique M., Gil J., Pons G., Lopez J.M. Transcriptional and translational control of Mcl-1 during apoptosis. Arch. Biochem. Biophys. 2003, 417:141-152.
27. Graff J.R., Zimmer S.G. Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin. Exp. Metast. 2003, 20:265-273.
28. Othumpangat S., Kashon M., Joseph P. Eukaryotic translation initiation factor 4E is a cellular target for toxicity and death due to exposure to cadmium chloride. J. Biol. Chem. 2005, 280:25162-25169.
29. Zhang S., Zhau H.E., Osunkoya O.A., Iqbal S., Yang X., Fan S., Chen Z., Wang R., Marshall F.F., Chung L.W., Wud D. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol. Cancer 2010, 9:9.
30. Chetoui N., Sylla K., Gagnon-Houde J.V., Alcaide-Loridan C., Charron D., Al-Daccak R., Aoudjit F. Down-regulation of mcl-1 by small interfering RNA sensitizes resistant melanoma cells to fas-mediated apoptosis. Mol. Cancer Res. 2008, 6:42-52.
31. Dash R., Azab B., Quinn B.A., Shen X., Wang X.Y., Das S.K., Rahmani M., Wei J., Hedvat M., Dent P., Dmitriev I.P., Curiel D.T., Grant S., Wu B., StebbinsL J.L., Pellecchia M., Reed J.C., Sarkar D., Fisher P.B. Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc. Natl. Acad. Sci. USA 2011, 108:8785-8790.
32. Oh S.J., Erb H.H., Hobisch A., Santer F.R., Culig Z. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr. Relat. Cancer 2012, 19:305-319.
33. Le Gouill S., Podar K., Harousseau J.L., Anderson K.C. Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 2004, 3:1259-1262.
34. Ding Q., Huo L., Yang J.Y., Xia W., Wei Y., Liao Y., Chang C.J., Yang Y., Lai C.C., Lee D.F., Yen C.J., Chen Y.J., Hsu J.M., Kuo H.P., Lin C.Y., Tsai F.J., Li L.Y., Tsai C.H., Hung M.C. Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer. Cancer Res. 2008, 68:6109-6117.
35. Jia Z., Zhang J., Wei D., Wang L., Yuan P., Le X., Li Q., Yao J., Xie K. Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A. Cancer Res. 2007, 67:4878-4885.